We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Pfizer, Abbott Laboratories, Union Pacific Corporation, Citigroup and Intuitive Surgical.
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 19, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer Inc. (PFE - Free Report) , Abbott Laboratories (ABT - Free Report) , Union Pacific Corporation (UNP - Free Report) , Citigroup Inc. (C - Free Report) and Intuitive Surgical, Inc. (ISRG - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Pfizer, Abbott Labs and Union Pacific
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc., Abbott Laboratories and Union Pacific Corporation. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Pfizer have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-13.9% vs. +14.6%), with the absence of credible growth drivers beyond the company's Covid offerings as the primary drag. Other issues like currency headwinds and pricing pressures are some of the other concerns.
Estimates have gone down slightly ahead of Q4 earnings. Pfizer has a mixed record of earnings surprises in the recent quarters. However, Pfizer boasts a diversified portfolio of innovative drugs and vaccines, including Ibrance and Prevnar.
Its COVID-19 vaccine and oral antiviral pill for COVID-19, Paxlovid have become a key contributor to the top line. Pfizer boasts a sustainable pipeline with multiple late-stage programs that can drive growth.
Abbott Laboratories shares have declined -10.1% over the past year against the Zacks Medical - Products industry's decline of -38.4%. The company's sales were negatively impacted by COVID-19 testing-related sales decline and a manufacturing stoppage initiated in February of certain infant nutrition formula products manufactured at Abbott's Sturgis, MI, facility.
However, excluding these negative factors, total worldwide sales increased 6% on an organic basis, benefitting from robust sales growth across the company's core Established Pharmaceuticals and Medical Devices segments.
Meanwhile, the Diabetes Care business continued to benefit from the growing sales of its flagship CGM system, FreeStyle Libre. The raised 2022 guidance buoys optimism.
Shares of Union Pacific have underperformed the Zacks Transportation - Rail industry over the past year (-10.5% vs. -5.2%). The company is facing escalation in fuel costs as oil prices move north is worrisome. This phenomenon induced a 22% rise in the operating expenses in the first nine months of 2022. Fuel costs surged 78% in the period. The same is likely to have been high in the December quarter as well. Detailed results will be out on Jan 24.
However, Union Pacific's efforts to reward its shareholders even in the current uncertain scenario please us. The company hiked dividend twice in 2021. In May 2022, UNP further upped its quarterly dividend by 10%. The railroad operator is also active on the buyback front.
Management expects share repurchases in 2022 to bearound $6.5 billion. UNP's strong free cash flow generating ability supports its shareholder-friendly activities. The uptick in overall volumes as labor woes ease is an added positive.
Other noteworthy reports we are featuring today include Citigroup Inc. and Intuitive Surgical, Inc..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Pfizer, Abbott Laboratories, Union Pacific Corporation, Citigroup and Intuitive Surgical.
For Immediate Release
Chicago, IL – January 19, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer Inc. (PFE - Free Report) , Abbott Laboratories (ABT - Free Report) , Union Pacific Corporation (UNP - Free Report) , Citigroup Inc. (C - Free Report) and Intuitive Surgical, Inc. (ISRG - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Pfizer, Abbott Labs and Union Pacific
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc., Abbott Laboratories and Union Pacific Corporation. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Pfizer have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-13.9% vs. +14.6%), with the absence of credible growth drivers beyond the company's Covid offerings as the primary drag. Other issues like currency headwinds and pricing pressures are some of the other concerns.
Estimates have gone down slightly ahead of Q4 earnings. Pfizer has a mixed record of earnings surprises in the recent quarters. However, Pfizer boasts a diversified portfolio of innovative drugs and vaccines, including Ibrance and Prevnar.
Its COVID-19 vaccine and oral antiviral pill for COVID-19, Paxlovid have become a key contributor to the top line. Pfizer boasts a sustainable pipeline with multiple late-stage programs that can drive growth.
(You can read the full research report on Pfizer here >>>)
Abbott Laboratories shares have declined -10.1% over the past year against the Zacks Medical - Products industry's decline of -38.4%. The company's sales were negatively impacted by COVID-19 testing-related sales decline and a manufacturing stoppage initiated in February of certain infant nutrition formula products manufactured at Abbott's Sturgis, MI, facility.
However, excluding these negative factors, total worldwide sales increased 6% on an organic basis, benefitting from robust sales growth across the company's core Established Pharmaceuticals and Medical Devices segments.
Meanwhile, the Diabetes Care business continued to benefit from the growing sales of its flagship CGM system, FreeStyle Libre. The raised 2022 guidance buoys optimism.
(You can read the full research report on Abbott Laboratories here >>>)
Shares of Union Pacific have underperformed the Zacks Transportation - Rail industry over the past year (-10.5% vs. -5.2%). The company is facing escalation in fuel costs as oil prices move north is worrisome. This phenomenon induced a 22% rise in the operating expenses in the first nine months of 2022. Fuel costs surged 78% in the period. The same is likely to have been high in the December quarter as well. Detailed results will be out on Jan 24.
However, Union Pacific's efforts to reward its shareholders even in the current uncertain scenario please us. The company hiked dividend twice in 2021. In May 2022, UNP further upped its quarterly dividend by 10%. The railroad operator is also active on the buyback front.
Management expects share repurchases in 2022 to bearound $6.5 billion. UNP's strong free cash flow generating ability supports its shareholder-friendly activities. The uptick in overall volumes as labor woes ease is an added positive.
(You can read the full research report on Union Pacific here >>>)
Other noteworthy reports we are featuring today include Citigroup Inc. and Intuitive Surgical, Inc..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.